• About
  • Subscribe
  • Advertise
  • Contact
Sunday, July 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Business

Glaucoma treatments change hands under pharmaceutical merger

by rhiannon bowman
September 30, 2020
in Business, Company updates & acquisitions, Glaucoma, Local, News, Therapies
Reading Time: 2 mins read
A A
The ACCC was concerned the merger would reduce competition for the supply of certain glaucoma products.

The ACCC was concerned the merger would reduce competition for the supply of certain glaucoma products.

Share on FacebookShare on Twitter

A proposed merger between two pharmaceutical companies that compete in the glaucoma treatment markets has been given the green light – with one major stipulation.

The Australian Competition and Consumer Commission (ACCC) has accepted a proposed merger between global pharmaceutical companies Mylan and Pfizer-owned Upjohn – whose combined businesses will be renamed Viatris – on the condition that they sell three off-patent branded pharmaceuticals in their portfolio to appease the ACCC’s competition concerns.

The off-patent products supplied to pharmacies and hospitals which are to be sold include two anti-glaucoma treatments with the active ingredients latanoprost and/or timolol, under the brand names Xalatan and Xalacom, and a cardiovascular treatment with the active ingredients amlodipine and/or atorvastatin, under the brand name Caduet.

The ACCC has approved Aspen as the buyer of the off-patent products, after an agreement was reached between Aspen and the merger parties, ensuring that competition that would have been lost will be replaced by competition from Aspen.

The ACCC was concerned the merger would significantly reduce competition for the supply of pharmaceutical products based on these active ingredients which are used to treat cardiovascular conditions and certain types of glaucoma.

The ACCC has approved Aspen as the buyer of the off-patent products to create competition that would have otherwise been reduced.

“For medicines based on latanoprost and latanoprost/timolol, we were concerned that remaining competitors would not be a sufficient constraint on the merged entity,” ACCC commissioner Mr Stephen Ridgeway said.

“Mylan and Upjohn are currently the only suppliers of amlodipine/atorvastatin, meaning the proposed merger would make the combined new firm, Viatris, the only supplier in the Australian market.”

He added: “Caduet, Xalatan and Xalacom are well established brands, and will provide the buyer with a strong opportunity to compete against the new combined firm Viatris.”

This merger is part of a global transaction that is also being considered by competition authorities in other jurisdictions.

In Australia, Mylan supplies a portfolio of approximately 350 generic pharmaceutical drugs and more than 450 branded, biosimilar medicines and over-the-counter remedies, while Upjohn supplies a portfolio of 18 pharmaceutical brands which are sold as off-patent products.

Aspen is currently the third largest pharmaceutical supplier by volume in the Australian market, operating from a manufacturing facility in Melbourne.

More reading

ACCC concludes investigation, clears Ellex-Lumibird deal

Oscar Wylee penalised $3.5 million following ACCC prosecution 

Tags: ACCCAspenAustralian Competition and Consumer CommissionglaucomalatanoprostMelbournemergerMylanPfizertimololUpjohnXalacomXalatan

Related Posts

So many companies working on so many solutions in IOLs and surgery means it has become evident that there is some nomenclature confusion.  Image: Oktay/stock.adobe.com.

Clearing up nomenclature confusion in IOL lenses

by Dr Peter Sumich
July 13, 2025

Presbyopia management has been the holy grail for intraocular lens technology development for 30 years, but sub-classifying lenses has become...

What the customer wants in a frame will not necessarily be suited to the prescription they end up with. Images: Jacobus Boshoff.

No, you can’t have that frame

by Jacobus Boshoff
July 12, 2025

Jacobus Boshoff on why a good optical dispenser sometimes needs to dish out the harsh truth, and why frame choice...

Myopia is surging around the world, and particularly among children. New studies show that HOYA's DIMS technology can have a lasting impact in treatment. Image: HOYA.

New evidence backs HOYA’s DIMS technology to combat myopia

by Staff Writer
July 11, 2025

HOYA Vision Care has announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited